Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non–small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Cascone, Tina, Kar, Gozde, Spicer, Jonathan D., García-Campelo, Rosario, Weder, Walter, Daniel, Davey B., Spigel, David R., Hussein, Maen, Mazieres, Julien, Oliveira, Julio, Yau, Edwin H., Spira, Alexander I., Anagnostou, Valsamo, Mager, Raymond, Hamid, Oday, Cheng, Lin-Yang, Zheng, Ying, Blando, Jorge, Tan, Tze Heng, Surace, Michael, Rodriguez-Canales, Jaime, Gopalakrishnan, Vancheswaran, Sellman, Bret R., Grenga, Italia, Soo-Hoo, Yee, Kumar, Rakesh, McGrath, Lara, Forde, Patrick M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618740/
https://www.ncbi.nlm.nih.gov/pubmed/37707791
http://dx.doi.org/10.1158/2159-8290.CD-23-0436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618740/
https://www.ncbi.nlm.nih.gov/pubmed/37707791
http://dx.doi.org/10.1158/2159-8290.CD-23-0436

Ejemplares similares